Since the discovery of MCC950 as an NLRP3 inhibitor, it’s been employed as a chemical tool to understand the pathological roles of the NLRP3 inflammasome in a variety of disease models including AD, atherosclerosis, asthma, allergic airway inflammation, inflammatory bowel disease (IBD), and many more (Dempsey et al., 2017; van der Heijden et al., 2017; van Hout et al., 2017; Ismael et al., 2018; Perera et al., 2018; Robinson et al., 2018; Xu et al., 2018; Zhai et al., 2018; Theofani et al., 2019; Fu et al., 2020; Ren et al., 2020). This evidence concerns the gene NLRP3 and asthma.